Cistrans interactions of cell surface receptors: biological roles and structural basis

  • Werner HeldEmail author
  • Roy A. Mariuzza
Multi-author review


Cell surface receptors bind ligands expressed on other cells (in trans) in order to communicate with neighboring cells. However, an increasing number of cell surface receptors are found to also interact with ligands expressed on the same cell (in cis). These observations raise questions regarding the biological role of such cis interactions. Specifically, it is important to know whether cis and trans binding have distinct functional effects and, if so, how a single cell discriminates between interactions in cis versus trans. Further, what are the structural features that allow certain cell surface receptors to engage ligand both on the same as well as on an apposed cell membrane? Here, we summarize known examples of receptors that display cistrans binding and discuss the emerging diversity of biological roles played by these unconventional two-way interactions, along with their structural basis.


NK cell receptor Ly49 LILRB/PIR-B MHC Notch Cis interaction Trans interaction NK cell education 



B cell receptor


B and T lymphocyte attenuator


Herpesvirus entry mediator




Leukocyte immunoglobulin-like receptor B


Major histocompatibility complex class I


Paired immunoglobulin-like receptor-B


Sialic acid-binding immunoglobulin-like lectin



W.H is supported in part by grants from the Swiss National Science Foundation and Oncosuissse. R.A.M. is supported by National Institutes of Health Grant AI47990.


  1. 1.
    Razi N, Varki A (1998) Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci USA 95:7469–7474PubMedCrossRefGoogle Scholar
  2. 2.
    Collins BE, Blixt O, DeSieno AR, Bovin N, Marth JD, Paulson JC (2004) Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci USA 101:6104–6109PubMedCrossRefGoogle Scholar
  3. 3.
    Collins BE, Blixt O, Han S, Duong B, Li H, Nathan JK, Bovin N, Paulson JC (2006) High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol 177:2994–3003PubMedGoogle Scholar
  4. 4.
    Han S, Collins BE, Bengtson P, Paulson JC (2005) Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat Chem Biol 1:93–97PubMedCrossRefGoogle Scholar
  5. 5.
    Doody GM, Justement LB, Delibrias CC, Matthews RJ, Lin J, Thomas ML, Fearon DT (1995) A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 269:242–244PubMedCrossRefGoogle Scholar
  6. 6.
    Jin L, McLean PA, Neel BG, Wortis HH (2002) Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J Exp Med 195:1199–1205PubMedCrossRefGoogle Scholar
  7. 7.
    Pillai S, Cariappa A, Pirnie SP (2009) Esterases and autoimmunity: the sialic acid acetylesterase pathway and the regulation of peripheral B cell tolerance. Trends Immunol 30:488–493PubMedCrossRefGoogle Scholar
  8. 8.
    Nitschke L (2009) CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev 230:128–143PubMedCrossRefGoogle Scholar
  9. 9.
    Doucey MA, Scarpellino L, Zimmer J, Guillaume P, Luescher IF, Bron C, Held W (2004) Cis-association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol 5:328–336PubMedCrossRefGoogle Scholar
  10. 10.
    Karlhofer FM, Ribaudo RK, Yokoyama WM (1992) MHC class I alloantigen specificity of Ly-49+ IL-2 activated natural killer cells. Nature 358:66–70PubMedCrossRefGoogle Scholar
  11. 11.
    Moretta A, Vitale M, Borrino C, Orengo A, Morelli L, Augugliaro R, Barbaresi M, Ciccone E, Moretta L (1993) P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specifities. J Exp Med 178:597–604PubMedCrossRefGoogle Scholar
  12. 12.
    Held W, Mariuzza R (2008) Cis interactions of immunoreceptors with MHC and non-MHC ligands. Nat Rev Immunol 8:269–278PubMedCrossRefGoogle Scholar
  13. 13.
    Yin Y, Yamashita Y, Noda H, Okafuji T, Go MJ, Tanaka H (2004) EphA receptor tyrosine kinases interact with co-expressed ephrin-A ligands in cis. Neurosci Res 48:285–296PubMedCrossRefGoogle Scholar
  14. 14.
    Masuda A, Nakamura A, Maeda T, Sakamoto Y, Takai T (2007) Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation. J Exp Med 204:907–920PubMedCrossRefGoogle Scholar
  15. 15.
    Cordle J, Johnson S, Tay JZ, Roversi P, Wilkin MB, de Madrid BH, Shimizu H, Jensen S, Whiteman P, Jin B, Redfield C, Baron M, Lea SM, Handford PA (2008) A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nat Struct Mol Biol 15:849–857PubMedCrossRefGoogle Scholar
  16. 16.
    Cheung TC, Oborne LM, Steinberg MW, Macauley MG, Fukuyama S, Sanjo H, D’Souza C, Norris PS, Pfeffer K, Murphy KM, Kronenberg M, Spear PG, Ware CF (2009) T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. J Immunol 183:7286–7296PubMedCrossRefGoogle Scholar
  17. 17.
    Haklai-Topper L, Mlechkovich G, Savariego D, Gokhman I, Yaron A (2010) Cis interaction between Semaphorin6A and Plexin-A4 modulates the repulsive response to Sema6A. EMBO J 29:2635–2645PubMedCrossRefGoogle Scholar
  18. 18.
    Ljunggren HG, Kärre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11:237–244PubMedCrossRefGoogle Scholar
  19. 19.
    Tormo J, Natarajan K, Margulies DH, Mariuzza RA (1999) Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand. Nature 402:623–631PubMedCrossRefGoogle Scholar
  20. 20.
    Matsumoto N, Mitsuki M, Tajima K, Yokoyama W (2001) The functional binding site for the C-type lectin-like natural killer cell receptor Ly49A spans three domains of its major histocompatibility complex class I ligand. J Exp Med 193:147–157PubMedCrossRefGoogle Scholar
  21. 21.
    Wang J, Whitman MC, Natarajan K, Tormo J, Mariuzza RA, Margulies DH (2002) Binding of the natural killer cell inhibitory receptor Ly49A to its major histocompatibility complex class I ligand. Crucial contacts include both H-2Dd and beta 2-microglobulin. J Biol Chem 277:1433–1442PubMedCrossRefGoogle Scholar
  22. 22.
    Back J, Chalifour A, Scarpellino L, Held W (2007) Stable masking by H-2Dd cis ligand limits Ly49A relocalization to the site of NK cell/target cell contact. Proc Natl Acad Sci USA 104:3978–3983PubMedCrossRefGoogle Scholar
  23. 23.
    Andersson KE, Williams GS, Davis DM, Hoglund P (2007) Quantifying the reduction in accessibility of the inhibitory NK cell receptor Ly49A caused by binding MHC class I proteins in cis. Eur J Immunol 37:516–527PubMedCrossRefGoogle Scholar
  24. 24.
    Hanke T, Takizawa H, McMahon CW, Busch DH, Pamer EG, Miller JD, Altman JD, Liu Y, Cado D, Lemonnier FA, Bjorkman PJ, Raulet DH (1999) Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 11:67–77PubMedCrossRefGoogle Scholar
  25. 25.
    Jonsson AH, Yang L, Kim S, Taffner SM, Yokoyama WM (2010) Effects of MHC class I alleles on licensing of Ly49A+ NK cells. J Immunol 184:3424–3432PubMedCrossRefGoogle Scholar
  26. 26.
    Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436:709–713PubMedCrossRefGoogle Scholar
  27. 27.
    Scarpellino L, Oeschger F, Guillaume P, Coudert JD, Levy F, Leclercq G, Held W (2007) Interactions of Ly49 family receptors with MHC class I ligands in trans and cis. J Immunol 178:1277–1284PubMedGoogle Scholar
  28. 28.
    Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito Y, Fujimura S, Koga T, Nakamura A, Takayanagi H, Itoi E, Takai T (2008) Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol 181:4742–4751PubMedGoogle Scholar
  29. 29.
    Tai LH, Goulet ML, Belanger S, Toyama-Sorimachi N, Fodil-Cornu N, Vidal SM, Troke AD, McVicar DW, Makrigiannis AP (2008) Positive regulation of plasmacytoid dendritic cell function via Ly49Q recognition of class I MHC. J Exp Med 205:3187–3199PubMedCrossRefGoogle Scholar
  30. 30.
    Yoshizaki M, Tazawa A, Kasumi E, Sasawatari S, Itoh K, Dohi T, Sasazuki T, Inaba K, Makrigiannis AP, Toyama-Sorimachi N (2009) Spatiotemporal regulation of intracellular trafficking of Toll-like receptor 9 by an inhibitory receptor, Ly49Q. Blood 114:1518–1527PubMedCrossRefGoogle Scholar
  31. 31.
    Sivori S, Falco M, Carlomagno S, Romeo E, Soldani C, Bensussan A, Viola A, Moretta L, Moretta A (2010) A novel KIR-associated fucntion: evidence rthat CpG DNA uptake and shuttling to early endosomes is mediated by KIR2DL2. Blood 116:1637–1647PubMedCrossRefGoogle Scholar
  32. 32.
    Takai T (2005) A novel recognition system for MHC class I molecules constituted by PIR. Adv Immunol 88:161–192PubMedCrossRefGoogle Scholar
  33. 33.
    Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M (1997) A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186:1809–1818PubMedCrossRefGoogle Scholar
  34. 34.
    Huang J, Goedert JJ, Sundberg EJ, Cung TD, Burke PS, Martin MP, Preiss L, Lifson J, Lichterfeld M, Carrington M, Yu XG (2009) HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. J Exp Med 206:2959–2966PubMedCrossRefGoogle Scholar
  35. 35.
    Endo S, Sakamoto Y, Kobayashi E, Nakamura A, Takai T (2008) Regulation of cytotoxic T lymphocyte triggering by PIR-B on dendritic cells. Proc Natl Acad Sci USA 105:14515–14520PubMedCrossRefGoogle Scholar
  36. 36.
    Olsson MY, Karre K, Sentman CL (1995) Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand. Proc Natl Acad Sci USA 92:1649–1653PubMedCrossRefGoogle Scholar
  37. 37.
    Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH (2005) A subset of natural killer cells achieve self-tolerance without expressing inhibitory receptors specific for self MHC molecules. Blood 105:4416–4423PubMedCrossRefGoogle Scholar
  38. 38.
    Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagne F, Ugolini S, Vivier E (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25:331–342PubMedCrossRefGoogle Scholar
  39. 39.
    Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR, Vlahiotis A, Piccirillo JF, Cella M, Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM (2008) HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA 105:3053–3058PubMedCrossRefGoogle Scholar
  40. 40.
    Ohlen C, Kling G, Höglund P, Hansson M, Scangos G, Bieberich C, Jay G, Kärre K (1989) Prevention of allogeneic bone marrow graft rejection by H-2 transgene in donor mice. Science 246:666–668PubMedCrossRefGoogle Scholar
  41. 41.
    Raulet DH, Vance RE (2006) Self-tolerance of natural killer cells. Nat Rev Immunol 6:520–531PubMedCrossRefGoogle Scholar
  42. 42.
    Chalifour A, Scarpellino L, Back J, Brodin P, Devèvre E, Gros F, Lévy F, Leclercq G, Höglund P, Beermann F, Held W (2009) A role for cis interaction between the inhibitory Ly49A receptor and MHC class I for NK cell education. Immunity 30:337–347PubMedCrossRefGoogle Scholar
  43. 43.
    Vyas YM, Maniar H, Lyddane CE, Sadelain M, Dupont B (2004) Ligand binding to inhibitory killer cell Ig-like receptors induce colocalization with Src homology domain 2-containing protein tyrosine phosphatase 1 and interruption of ongoing activation signals. J Immunol 173:1571–1578PubMedGoogle Scholar
  44. 44.
    Fourmentraux-Neves E, Jalil A, Da Rocha S, Pichon C, Chouaib S, Bismuth G, Caignard A (2008) Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells. Blood 112:2381–2389PubMedCrossRefGoogle Scholar
  45. 45.
    Tripathy SK, Keyel PA, Yang L, Pingel JT, Cheng TP, Schneeberger A, Yokoyama WM (2008) Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J Exp Med 205:1829–1841PubMedCrossRefGoogle Scholar
  46. 46.
    Egea J, Klein R (2007) Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol 17:230–238PubMedCrossRefGoogle Scholar
  47. 47.
    Sprinzak D, Lakhanpal A, Lebon L, Santat LA, Fontes ME, Anderson GA, Garcia-Ojalvo J, Elowitz MB (2010) Cis-interactions between Notch and Delta generate mutually exclusive signalling states. Nature 465:86–90PubMedCrossRefGoogle Scholar
  48. 48.
    Montgomery RI, Warner MS, Lum BJ, Spear PG (1996) Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87:427–436PubMedCrossRefGoogle Scholar
  49. 49.
    Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML (1997) A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7:273–282PubMedCrossRefGoogle Scholar
  50. 50.
    Back J, Malchiodi EL, Cho S, Scarpellino L, Schneider P, Kerzic MC, Mariuzza RA, Held W (2009) Distinct conformations of Ly49 natural killer cell receptors mediate MHC class I recognition in trans and cis. Immunity 31:598–608PubMedCrossRefGoogle Scholar
  51. 51.
    Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH (2002) Structure and function of natural killer cell receptors: multiple solutions to self, nonself discrimination. Annu Rev Immunol 20:853–885PubMedCrossRefGoogle Scholar
  52. 52.
    Deng L, Mariuzza RA (2006) Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors. Semin Immunol 18:159–166PubMedCrossRefGoogle Scholar
  53. 53.
    Meijers R, Puettmann-Holgado R, Skiniotis G, Liu JH, Walz T, Wang JH, Schmucker D (2007) Structural basis of Dscam isoform specificity. Nature 449:487–491PubMedCrossRefGoogle Scholar
  54. 54.
    Schwartz JC, Zhang X, Nathenson SG, Almo SC (2002) Structural mechanisms of costimulation. Nat Immunol 3:427–434PubMedCrossRefGoogle Scholar
  55. 55.
    Deng L, Cho S, Malchiodi EL, Kerzic MC, Dam J, Mariuzza RA (2008) Molecular architecture of the MHC-binding site of Ly49 natural killer cell receptors. J Biol Chem 283:16840–16849PubMedCrossRefGoogle Scholar
  56. 56.
    Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD (2000) Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 405:537–543PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2011

Authors and Affiliations

  1. 1.Ludwig Center for Cancer Research of the University of LausanneEpalingesSwitzerland
  2. 2.University of Maryland Biotechnology Institute for Bioscience and Biotechnology ResearchRockvilleUSA
  3. 3.Department of Cell Biology and Molecular GeneticsUniversity of MarylandCollege ParkUSA

Personalised recommendations